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Abstract The occurrence of the novel proposed endocannabi-
noid, noladin ether (2-arachidonyl glyceryl ether, 2-AGE) in
various rat organs and brain regions, and its inactivation by
intact C6 glioma cells, were studied. 2-AGE was measured by
isotope dilution liquid chromatography-atmospheric pressure
chemical ionization-mass spectrometry, with a detection limit
of 100 fmol. A compound with the same mass and chromato-
graphic/chemical properties as 2-AGE was found in whole brain,
with the highest amounts in the thalamus and hippocampus.
Synthetic [3H]2-AGE was inactivated by intact rat C6 glioma
cells by a time- and temperature-dependent process consisting of
cellular uptake and partial incorporation into phospholipids.
Further data suggested that 2-AGE is taken up by cells via the
anandamide/2-arachidonoyl glycerol (2-AG) membrane trans-
porter(s), and biosynthesized in a different way as compared to 2-
AG. ß 2002 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
Anandamide (arachidonoylethanolamide, AEA [1]) and 2-
arachidonoyl glycerol (2-AG; [2,3]) are the best known endog-
enous ligands of cannabinoid receptors, and are also known
as endocannabinoids. While AEA activates the CB1 cannabi-
noid receptor, which is most abundant in the brain, and less
e⁄caciously the CB2 cannabinoid receptor, which is present
almost uniquely in immune cells, 2-AG exhibits similar a⁄nity
for and e⁄cacy at both cannabinoid receptors (see [4,5], for
reviews). Recently, another putative endocannabinoid was
found in porcine brain [6]. This is 2-arachidonyl glyceryl ether
(noladin ether, 2-AGE) and has a chemical structure unpre-
cedented in nature. In fact, all glyceryl ethers previously iden-
ti¢ed belong to the sn-1-alkyl type, and are the hydrolysis
products, or the biosynthetic precursors, of the plasmalogens
(Fig. 1).
The 2-AGE binds selectively to CB1 vs. CB2 cannabinoid
receptors, functionally activates CB1 receptors, and induces
responses typical of cannabimimetic compounds in the mouse
‘tetrad’ of behavioral tests in vivo [6,7]. Evidence of de novo
biosynthesis and inactivation in brain cells is, however, neces-
sary before 2-AGE can reach the status of an endogenous
neuronal mediator. Both these criteria are ful¢lled by AEA
and 2-AG, which are produced from arachidonic acid (AA)-
containing phospholipid precursors when neurons are stimu-
lated with depolarizing agents such as ionomycin, and are
inactivated by facilitated di¡usion into neurons and astro-
cytes, followed by enzymatic hydrolysis and/or re-esteri¢cative
recycling into phospholipids [8^10]. One, or two distinct and
functionally very similar, membrane transporter(s) mediate(s)
the cellular uptake of AEA and 2-AG [11]. One enzyme, the
‘fatty acid amide hydrolase’ [12], is mostly responsible for
both AEA and 2-AG hydrolysis in neuronal cells [10,13].
Nothing is known to date on the mechanisms underlying
the biosynthesis and inactivation of 2-AGE. To address this
issue we have investigated if 2-AGE is present in rat brain,
how it is distributed among distinct brain regions, and if its
biosynthesis and inactivation in neuronal and glial-like cells
occur through processes similar to those previously described
for 2-AG.
2. Materials and methods
2.1. Materials
d0-, d8- and [3H]2-AGE were synthesized as described previously
[6], starting from AA (Sigma), d8-AA (Sigma) and [3H]AA respec-
tively (NEN Life Sciences, 187 Ci/mmol). In the case of [3H]2-AGE,
[3H]AA (10 WCi) was diluted with 4 Wmol of AA to obtain a ¢nal
speci¢c activity of 2.5 WCi/Wmol. The compounds were puri¢ed by
open bed silica chromatography [9]. AEA, 2-AG, [14C]AEA and
[3H]2-AG were synthesized as described previously [1,2,9]. d8-2-AG
and d8- AEA were purchased from Cayman. N18TG2, RBL-2H3 and
C6 cells were cultured as described [9,11,14].
2.2. Gas chromatography and liquid chromatography-mass
spectrometric analysis of 2-AGE
Analysis of synthetic 2-AGE and d8-2-AGE by gas chromatogra-
phy-electron impact mass spectrometry (GC-EIMS) was carried out as
described previously [9] after derivatization with 15 Wl N-methyl-N-
trimethylsilyl-tri£uoroacetamide containing 1% trimethyl chlorosilane
for 2 h at room temperature, thus yielding the bis-trimethylsilyl
(TMS) derivatives. Analysis was carried out also by high performance
liquid chromatography-atmospheric pressure chemical ionizaion-mass
spectrometry (HPLC-APCI-MS) by using a Shimadzu HPLC appara-
tus (LC-10ADVP) coupled to a Shimadzu (LCMS-2010) quadrupole
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MS via a Shimadzu APCI interface. MS analyses were carried out
either in the full scan or the select ion monitoring (SIM) mode. The
temperature of the APCI source was 400‡C; the HPLC column was a
Phenomenex (5 Wm, 150U4.5 mm) reverse phase (RP) column, eluted
with an isocratic step of methanol:water:acetic acid (85:15:0.1, by
volume) at a £ow rate of 1 ml/min. Tissues from adult male
Sprague^Dawley rats were dissected within 5 min from decapitation
and immediately frozen at 380‡C, and lipid extracts were obtained
and pre-puri¢ed as described previously [9].
2.3. Biosynthesis experiments
Almost con£uent N18TG2 cells in 10 cm Petri dishes were incu-
bated overnight with [3H]AA (0.2 WCi/ml in serum-supplemented cul-
ture medium), and then washed twice with serum-free medium prior
to stimulation with 3 WM ionomycin (Sigma, in 3 ml/dish of serum-
free medium) for 10 min at 37‡C. Ten dishes (about 50U106 cells) for
each data point were used. After the incubation 2 ml of ice-cold
methanol were added to each dish, cells were transferred to 50 ml
Falcon tubes, and 2 ml chloroform were added. The mixture was
sonicated for 3 min, and the organic phase separated from debris
by centrifugation at 1000 rpm. The organic phase was lyophilized
and pre-puri¢ed by open bed chromatography as described elsewhere
[9]. RP-HPLC of the extracts was carried out as by using a semi-
preparative Spherisorb column [9] eluted with methanol:water (92:8
by volume), at a £ow rate of 2 ml/min. Under these conditions syn-
thetic standards of AEA, 2-AG and 2-AGE are eluted after 21, 22 and
29 min. Each HPLC fraction was transferred into scintillation vials,
5 ml of scintillation liquid added, and radioactivity counted by a
L counter.
2.4. Inactivation experiments
Con£uent C6 or RBL-2H3 cells in 6U multi-well dishes were in-
cubated with [3H]2-AGE (10 000 cpm in 0.5 ml, 7 WM) for increasing
intervals of time (0, 5, 15 and 30 min) at 37‡C or 0‡C. In a second set
of experiments C6 cells were incubated for 10 min at 37‡C with [3H]2-
AGE at increasing concentrations (0, 0.5, 1, 5, 10, 50 WM). In another
series of experiments, cells were incubated for 10 min at 37‡C with
[3H]2-AGE (2 WM) with or without 30 WM AEA or 2-AG. In a fourth
set of experiments, cells were incubated for 10 min at 37‡C with either
[3H]2-AG (4 WM) or [14C]AEA (4 WM) with or without increasing
concentrations (1, 10, 25 and 50 WM) of 2-AGE. In each experiment
the incubation was terminated by lowering the temperature at 4‡C.
In the ¢rst set of experiments, [3H]2-AGE amounts in the incubation
medium were determined after extraction with chloroform:methanol
(2:1 by volume) followed by thin layer chromatography (TLC)
on silica gel polyethylene plates (Merck) eluted with the organic
phase of ethyl acetate:water:2,2,4-trimethyl-pentane:acetic acid
(39.3:35.7:17.8:7.2 by volume). The amounts of [3H]2-AGE,
[3H]phospholipids and [3H]AA+[3H]diacylglycerols+[3H]triacyl-
glycerols in the cells was determined after extraction of the cells
with chloroform/methanol/DMEM (2:1:1 by volume), followed by
TLC on polyethylene plates eluted with the solvent system described
above. In the second and third series of experiments, the amount of
residual extracellular [3H]2-AGE was determined after extraction and
puri¢cation of the medium as described above, and used to calculate
the amount taken up by cells. The uptake observed at 4‡C was kept
into account for the calculation of net uptake at 37‡C. In the fourth
set of experiments, the amount of residual [3H]2-AG or [14C]AEA in
the incubation medium was determined as described previously [11].
In all cases, the radioactivity contained in each lipid component was
determined by cutting the corresponding TLC bands, transferring
them to scintillation vials, adding 1 ml methanol followed by 5 ml
scintillation liquid, and counting by a L counter.
3. Results and discussion
In order to undertake this study we needed a sensitive tech-
nique to measure 2-AGE levels in little amounts of tissue. We
synthesized d8-2-AGE from d8-AA by a procedure previously
described [6]. The identity and purity of synthetic d8-2-AGE
were checked by means of GC-EIMS of its TMS derivative,
which yielded a single peak with a retention time of 15.91 min
identical to that of 2-AGE-TMS. This peak exhibited an
EI-MS spectrum identical to that reported by Hanus and
co-workers for synthetic 2-AGE-TMS [6] except for the ex-
pected 8 mass unit shift of the molecular ion at m/z = 516 and
of the acyl fragments (m/z = 280, 297, 323, 370 and 413). No
mass shift was observed in the fragment corresponding to the
glyceryl moiety at m/z = 219. The amount of synthetic d8-2-
AGE was determined by GC-EIMS of the TMS derivative
after dilution with a known amount of synthetic 2-AGE-
TMS. d8-2-AGE was then analyzed by LC-MS by using the
full scan mode. While 2-AGE exhibited a retention time of
14.9 min and a most abundant fragment at m/z = 365.3, cor-
responding to the M+1 ion, d8-2-AGE displayed an almost
identical retention time (14.7 min) and a cluster of fragment
ions from m/z = 366.3 up to 374.3, the most abundant of
which was at m/z = 369.3, corresponding to the M+1 ion of
d4-2-AGE (data not shown). This was very likely due to pro-
ton^deuterium exchange with the solvent at the high temper-
ature of the APCI source. The two regio-isomers of 2-AGE,
1-AGE and 3-AGE were both eluted 3.8 min after 2-AGE
under the same chromatographic conditions. For LC-MS
analysis of 2-AGE, increasing amounts (100, 500, 1000,
2000 and 4000 fmol) of the synthetic non-deuterated com-
pound were diluted with 500 fmol of d8-2-AGE and MS anal-
ysis carried out in the SIM mode by monitoring m/z = 365.3,
369.3 and 373.3 (d8-2-AGE). Over this range of 2-AGE
amounts the ratios between the areas of the LC-MS peaks
at m/z = 365.3 and 369.3, and at m/z = 365.3 and 373.3 varied
in a linear way with varying concentrations of 2-AGE (data
not shown). The detection limit of this method was V100
fmol of d8-2-AGE.
We next analyzed with this LC-MS method the amounts of
the native compound in lipid extracts from di¡erent rat or-
gans. To prevent the over-load of the HPLC column only a
part (5^50%) of the puri¢ed extracts was analyzed. Therefore,
the actual detection limit of our method was V2 pmol/g for
Fig. 1. Chemical structures of noladin ether (2-AGE) together with
a more frequently found sn-1-alkyl-glyceryl ether, and the two previ-
ously discovered endocannabinoids, 2-AG and AEA.
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the organs and 200 fmol/g wet tissue weight for the brain
areas. The brain was the only organ where we found measur-
able amounts (25.4 þ 3.8 pmol/g of whole brain wet tissue) of
a HPLC component with the same molecular weight as 2-
AGE and the same retention time as d8-2-AGE (Fig. 2). De-
rivatization of puri¢ed brain lipid extract with formation of
TMS derivatives led to the disappearance of this component
from LC-MS chromatograms, and to the appearance of a
component in GC-EIMS analyses with the same retention
time and fragment ions (m/z = 272, 289, 315, 362, see above)
as synthetic 2-AGE (data not shown). By using the same LC-
MS method, and by monitoring the ions at m/z = 356.2 and
387.3 (M+1 for d8-AEA and d8-2-AG) and 348.2 and 379.3
(M+1 for AEA and 2-AG), we quanti¢ed also endogenous
AEA and 2-AG in whole brain (26.3 þ 5.2 pmol/g and
4.5 þ 1.1 nmol/g, respectively). These compounds, but not 2-
AGE, were also found in the spleen, heart and liver (data not
shown). Taken together, the tissue-speci¢c occurrence of 2-
AGE in the brain, its selectivity for CB1 vs. CB2 receptors
[6], and the high concentration of CB1 receptors in the brain
as compared to other tissues, support the hypothesis that this
compound is an endogenous CB1 receptor ligand. The region-
al distribution of 2-AGE in rat brain overlapped only in part
with that of cannabinoid CB1 receptors, or with that of AEA
and 2-AG [15], with the thalamus and the hippocampus ex-
hibiting the highest concentrations, and the cerebellum, spinal
cord and brainstem the lowest (Table 1).
Having demonstrated that a 2-AGE-like lipid is present in
rat brain, we next wanted to assess whether this compound,
like 2-AG [9], is produced on stimulation of N18TG2 cells
with ionomycin. We found that treatment of [3H]AA-prela-
belled cells with 3 WM ionomycin leads to the formation of de
novo synthesized [3H]2-AG, but of very little, if any, [3H]2-
AGE (from 209 þ 90 to 450 þ 125 cpm for 2-AG, P6 0.05 by
ANOVA, and from 35 þ 15 to 63 þ 14 cpm for 2-AGE, not
signi¢cant by ANOVA, means þ S.D., n = 3). These data sug-
gest that the biochemical mechanism for the synthesis of 2-
AGE might be di¡erent from that of 2-AG [16], as indicated
also by the di¡erent brain regional distribution of the two
compounds (Table 1). It is possible that Ca2 entry and neu-
ronal membrane depolarization do not trigger 2-AGE biosyn-
thesis, or that this process is not dependent on AA-containing
precursors. The latter possibility is rather unlikely since, in the
case of sn-1-alkyl-glycerols, it was shown that these com-
pounds derive ultimately from the corresponding fatty acids
via the fatty acid alcohols ([17] for review). On the other
hand, the possibility that 2-AGE is not produced on Ca2
in£ux into neurons, under conditions su⁄cient to elicit endo-
cannabinoid biosynthesis, might suggest that this novel com-
pound is not produced during neuronal depolarization. More
in-depth experiments are needed in order to understand the
pathway for 2-AGE biosynthesis and whether it is regulated
by [Ca2]i-modulating stimuli di¡erent from Ca2 ionophores.
Finally, we wanted to determine if at least the mechanisms
for 2-AGE disposal by living cells are similar to those previ-
ously described for AEA and 2-AG. Clearly, 2-AGE, unlike
the other two endocannabinoids, is not likely to be hydrolyzed
enzymatically. If other means for the degradation of this com-
pound were lacking, this property of 2-AGE would strongly
argue against a role for this compound as an endogenous
mediator. However, we found here that [3H]2-AGE could be
e⁄caciously taken up in a time-, concentration- and temper-
ature-dependent manner by intact C6 glioma and RBL-2H3
cells (t1=2V5 min, Fig. 3A and data not shown), where an
AEA membrane transporter was previously partially charac-
terized [9,11]. The apparent Km and Vmax for [3H]2-AGE up-
take were 12.8 þ 2.1 WM and 0.21 þ 0.08 nmol min31 mg
protein31 (means þ S.D., n = 3), which were comparable to
those previously described for 2-AG in the same cells [11].
A minor part (V10%) of [3H]2-AGE taken up by C6 cells
was transformed into phospholipids as well as into a lipid
mixture with the same mobility on TLC as AA, diacylglycer-
ols and triacylglycerols (Fig. 3B). The small amounts available
Fig. 2. LC-MS chromatogram of a puri¢ed lipid extract from rat brain diluted with 250 fmol of synthetic d8-2-AGE. APCI-MS was run in the
selected ion monitoring mode at the m/z values corresponding to the molecular weight+1 of 2-AGE (365.3), d8-2-AGE (373.3) and d4-2-AGE
(369.3), formed from the deuterium^proton exchange of d8-2-AGE. The retention time of synthetic 2-AGE, as determined after the analysis of
the lipid extract, is shown. Synthetic standards of the two regio-isomers of 2-AGE, 1-AGE and 3-AGE were both eluted 3.8 min after 2-AGE
under the same chromatographic conditions The chromatogram is representative of two distinct analyses.
Table 1
Concentration of 2-AGE and 2-AG in several rat brain regions as
determined by isotope dilution LC-MS
Brain region 2-AGE (pmol/g) 2-AG (nmol/g)
Thalamus 64.5 þ 4.0 6.5 þ 3.1
Hippocampus 57.9 þ 28.5 4.4 þ 0.4
Striatum 29.5 þ 6.9 3.0 þ 1.1
Cerebral cortex 10.1 þ 1.5 5.6 þ 1.0
Brainstem 4.3 þ 2.1 3.3 þ 0.9
Spinal cord 1.4 þ 0.8 7.8 þ 0.2
Cerebellum N.D. 14.6 þ 0.2
Data are means þ S.D. (n = 2). N.D., not detectable. The whole cere-
bral cortex was used.
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of this mixture prevented its further characterization. How-
ever, if the analogy between 2-AGE and sn-1-alkyl-glycerol
ethers is to be pushed further, it is more likely that the major
metabolic pathway of this novel endocannabinoid consists of
the acylation of the sn-1 and/or sn-3 hydroxy groups [17].
Furthermore, 2-AG is also directly re-esteri¢ed into glycero-
lipids [10]. Interestingly, no radioactive band other than those
described above could be detected in TLC analyses of C6 cell
extracts after incubation with [3H]2-AGE.
C6 cells were previously shown to contain one or two dis-
tinct, albeit functionally very similar, membrane transporters
for the uptake of AEA and 2-AG [11]. Therefore, we exam-
ined whether the uptake of 2-AGE by these cells was mediated
by this(ese) transporter(s). 2-AGE dose-dependently inhibited
the uptake of both [14C]AEA and [3H]2-AG by C6 cells, with
estimated Ki values of 15.6 þ 2.3 and 22.2 þ 2.7 WM, respec-
tively (means þ S.D., n = 3). Under the same conditions, AEA
and 2-AG inhibited [14C]AEA and [3H]2-AG uptake by the
same cells with Ki values ranging between 13.4 and 30.1 WM,
respectively [11]. These observations suggest that 2-AGE may
di¡use through the cell membrane by means of the previously
identi¢ed AEA/2-AG transporter(s), and this hypothesis was
supported by the ¢nding that AEA and 2-AG (30 WM) pro-
duced a 47.9 þ 3.5 and 41.3 þ 3.9% inhibition of [3H]2-AGE
uptake by C6 cells, respectively (P6 0.01 by ANOVA,
means þ S.D., n = 3).
Fig. 3. Inactivation of [3H]2-AGE by intact C6 glioma cells. Cells were incubated for increasing intervals of time, and either at 37‡C or 0‡C,
with synthetic [3H]2-AGE (10 000 Cpm, 7 WM). The amounts of (A) residual [3H]2-AGE in the incubation medium and of unmetabolized
[3H]2-AGE found in cells, and (B) [3H]radioactivity found in TLC bands corresponding to phospholipids (Rf = 0^0.1) or AA+diacylglycer-
ols+triacylglycerols (Rf = 0.9^1.0), are shown for each time point. Data are means of n = 3 experiments carried out in duplicate. Error bars are
not shown for the sake of clarity and were never higher than 5% of the means.
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In conclusion, we have developed a method for the quanti-
¢cation of 2-AGE in tissues, and have presented evidence for
the occurrence in rat brain of a lipid substance with the same
chromatographic mobility, molecular weight and chemical be-
havior as 2-AGE. The brain concentration of 2-AGE is sim-
ilar to that of AEA and lower than that of 2-AG, and its
brain regional distribution re£ects that of CB1 receptors
only in part. In glial cells 2-AGE was: (1) rapidly taken up
from the extracellular medium, very likely through the same
proteins that facilitate AEA and 2-AG re-uptake; and (2)
slowly metabolized into phospholipids, thus supporting the
role of this novel metabolite as an endogenous mediator.
The way 2-AGE is biosynthesized in the CNS remains, how-
ever, still unexplored, and represents an interesting area for
further investigations.
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